Sanofi India

Why is Sanofi India Ltd falling/rising?

As of 09-Aug, Sanofi India Ltd's stock price is 3,345.50, down 0.17%, with a significant annual decline of 35.48%, underperforming the Sensex. Despite being net-debt free and having a high ROE of 50.57%, the stock's overall sentiment remains negative, influenced by bearish trends and decreased investor participation.

As of 09-Aug, Sanofi India Ltd's stock price is currently at 3,345.50, reflecting a decrease of 5.65 (-0.17%). The stock has shown a significant decline over the past year, with a return of -35.48%, which is considerably worse than the benchmark Sensex, which has only decreased by 2.63% during the same period. Additionally, the year-to-date performance shows a decline of -18.24% compared to the Sensex's -7.89%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by -0.42%. The moving averages suggest that while the stock is higher than the 50-day moving average, it is lower than the 5-day, 20-day, 100-day, and 200-day moving averages, indicating a bearish trend in the short to medium term. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by -15.46% against the 5-day average.<BR><BR>Despite these negative indicators, there are some positive aspects to consider. The company is net-debt free and has a high return on equity (ROE) of 50.57%, which reflects strong management efficiency. Additionally, the stock offers a high dividend yield of 3.67%, which may attract some investors looking for income. However, the overall sentiment appears to be negative, contributing to the stock's decline.

Which are the latest news on Sanofi India?

Should I buy, sell or hold Sanofi India Ltd?

How big is Sanofi India?

As of 10th June, Sanofi India Ltd has a market capitalization of 7,354.00 Cr, with recent net sales of 2,038.30 Cr and net profit of 396.20 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Sanofi India Ltd has a market capitalization of 7,354.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,038.30 Cr, while the sum of Net Profit for the same period is 396.20 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is December 2024. Shareholder's Funds are valued at 860.60 Cr, and Total Assets amount to 1,611.70 Cr.

Who are in the management team of Sanofi India?

The management team of Sanofi India includes Chairman Aditya Narayan, Whole Time Director & CFO Vaibhav Karandikar, Managing Director Rodolfo Hrosz, and several independent directors, among others, who guide the company's strategic direction and operations.

The management team of Sanofi India includes the following key individuals:<BR><BR>1. **Aditya Narayan** - Chairman & Independent Director<BR>2. **Usha Thorat** - Independent Director<BR>3. **Vaibhav Karandikar** - Whole Time Director & CFO<BR>4. **Rahul Bhatnagar** - Independent Director<BR>5. **Marc-Antoine Lucchini** - Director<BR>6. **Annapurna Das** - Director<BR>7. **Rodolfo Hrosz** - Managing Director<BR>8. **Radhika Shah** - Company Secretary<BR>9. **Renee Amonkar** - Whole Time Director & Additional Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Sanofi India?

Sanofi India's peers include Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., SPARC, FDC, Aarti Pharma, Senores Pharma, and Innova Captab. Senores Pharma leads in 1-year returns at 117.67%, while Sanofi India has the lowest at -48.66%.

Peers: The peers of Sanofi India are Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., SPARC, FDC, Aarti Pharma, Senores Pharma., and Innova Captab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India, Blue Jet Health, Supriya Lifesci., and Innova Captab, while Average management risk is found at Akums Drugs, Strides Pharma, SPARC, FDC, Aarti Pharma, and Senores Pharma. Growth is Excellent at SPARC and Senores Pharma, while Below Average growth is noted for Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, FDC, Aarti Pharma, and Innova Captab. Good capital structure is seen at Blue Jet Health, Supriya Lifesci., and Senores Pharma, while Excellent capital structure is attributed to Sanofi India, FDC, Aarti Pharma, and Innova Captab, and the rest have Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma at 117.67%, while Sanofi India has the lowest at -48.66%. This indicates that Sanofi India's 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for Blue Jet Health, Sanofi India, FDC, Aarti Pharma, and Strides Pharma.

What does Sanofi India do?

Sanofi India Ltd is a multinational pharmaceutical and biotechnology company engaged in manufacturing and trading drugs, with a market cap of INR 7,354 Cr. As of March 2026, it reported net sales of 472 Cr and a net profit of 103 Cr.

Overview: <BR>Sanofi India Ltd is a leading multinational company in the Pharmaceuticals & Biotechnology industry, primarily engaged in the manufacturing and trading of drugs and pharmaceuticals, categorized as a Small Cap.<BR><BR>History: <BR>Sanofi India Limited was incorporated in May 1956 and was previously known as Aventis Pharma Limited until it changed its name on May 11, 2012. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 472 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 103 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 7,354 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 19.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 3.91% <BR>Debt-Equity: -0.41 <BR>Return on Equity: 48.73% <BR>Price to Book: 10.71 <BR><BR>Contact Details: <BR>Address: Sanofi Hse 117-B Saki Vihar Rd, L&T Business Park Powai Mumbai Maharashtra : 400072 <BR>Phone: 91-22-28032000 <BR>Email: igrc.sil@sanofi.com <BR>Website: http://www.sanofiindialtd.com

Has Sanofi India declared dividend?

Yes, Sanofi India Ltd has declared a dividend of 750% (₹117 per share) with an ex-date of November 7, 2025. Despite the dividend, the company's stock has shown negative total returns across various periods, indicating challenges in performance.

Sanofi India Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 750%<BR>- Amount per share: 117<BR>- Ex-date: 07 Nov 25<BR><BR>Dividend Yield: 2.47%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -18.68%, the dividend return was 1.35%, resulting in a total return of -17.33%.<BR><BR>Over the past 6 months, the price return was -18.91%, the dividend return was 1.28%, leading to a total return of -17.63%.<BR><BR>For the 1-year period, the price return was -26.88%, with a dividend return of 2.88%, culminating in a total return of -24.0%.<BR><BR>In the 2-year period, the price return was -35.48%, the dividend return was 4.63%, resulting in a total return of -30.85%.<BR><BR>During the last 3 years, the price return was -13.85%, the dividend return was 9.68%, leading to a total return of -4.17%.<BR><BR>Over the 4-year period, the price return was -42.23%, with a dividend return of 12.88%, resulting in a total return of -29.35%.<BR><BR>In the 5-year period, the price return was -40.07%, the dividend return was 15.46%, culminating in a total return of -24.61%.<BR><BR>Overall, while Sanofi India has declared a substantial dividend, the total returns over various periods indicate a trend of negative performance, particularly in price returns, suggesting challenges in the company's stock performance despite the dividend payouts.

Are Sanofi India latest results good or bad?

Sanofi India's latest results are mixed; while net profit increased by 11.07% quarter-on-quarter, it fell 45.89% year-on-year, raising concerns about profitability. Despite stable operating margins and strong return on equity, the overall outlook appears more negative due to significant earnings challenges.

Sanofi India's latest results present a mixed picture. In Q2 FY26, the company reported a net profit of ₹82.20 crores, which is an 11.07% increase compared to the previous quarter. However, this figure represents a significant decline of 45.89% year-on-year, indicating serious challenges in profitability.<BR><BR>On the sales front, net sales for the quarter were ₹524.00 crores, reflecting a slight decrease of 1.74% from the previous quarter, although there was a year-on-year growth of 6.79%. This volatility in revenue is concerning, especially following a previous quarter that showed recovery.<BR><BR>Operating margins remained relatively stable at 22.84%, down slightly from the previous quarter, but still indicative of the company's ability to maintain efficiency in a challenging market. The return on equity is strong at 35.83%, which is among the best in the industry, highlighting effective capital utilization.<BR><BR>Overall, while there are some positive aspects such as sequential profit growth and strong operating margins, the sharp year-on-year decline in net profit raises significant concerns about the company's earnings sustainability. The combination of these factors suggests that the results are more negative than positive, reflecting ongoing struggles in the current market environment.

How has been the historical performance of Sanofi India?

Sanofi India's historical performance for the fiscal years ending December 2023 and 2024 shows slight growth in net sales and operating income, but declines in profitability metrics, including net profit and earnings per share. Total liabilities and assets also decreased, while cash flow from operations improved.

Answer:<BR>The historical performance of Sanofi India shows a mixed trend in its financial metrics for the years ending December 2023 and December 2024.<BR><BR>Breakdown:<BR>In the fiscal year ending December 2024, Sanofi India reported net sales of 2,013.20 crore, a slight increase from 1,996.10 crore in December 2023. Total operating income also rose to 2,013.20 crore from 1,996.10 crore. However, total expenditure increased to 1,522.40 crore from 1,508.40 crore, leading to an operating profit (PBDIT) of 507.30 crore, down from 548.90 crore the previous year. Profit before tax decreased to 431.40 crore from 528.50 crore, and profit after tax fell to 313.70 crore from 364.60 crore. The consolidated net profit also declined to 413.30 crore from 602.90 crore. Earnings per share dropped to 179.7 from 262.13, reflecting a decrease in profitability. On the balance sheet, total liabilities decreased to 1,611.70 crore from 1,714.80 crore, while total assets also fell to 1,611.70 crore from 1,714.80 crore. Cash flow from operating activities improved to 461.00 crore from 230.00 crore, but cash and cash equivalents at year-end decreased to 283.00 crore from 394.00 crore. Overall, while sales and operating income showed slight growth, profitability metrics and cash reserves reflected a downturn.

When is the next results date for Sanofi India?

Sanofi India will announce its results on 29 October 2025.

Sanofi India will declare its results on 29 October 2025.

Is Sanofi India overvalued or undervalued?

As of August 26, 2025, Sanofi India is fairly valued with a PE ratio of 33.02, an EV to EBITDA of 22.78, and a ROE of 41.43%, showing better valuation compared to peers like Sun Pharma and Divi's Lab, despite underperforming against the Sensex with a year-to-date return of -16.18%.

As of 26 August 2025, the valuation grade for Sanofi India has moved from expensive to fair. Based on the analysis, the company is currently fairly valued. Key ratios include a PE ratio of 33.02, an EV to EBITDA of 22.78, and a ROE of 41.43%. <BR><BR>In comparison to its peers, Sanofi India's PE ratio is slightly lower than Sun Pharma's at 33.48, while it is significantly more favorable than Divi's Lab, which stands at 71.33. Additionally, the PEG ratio for Sanofi is 0.00, indicating a potential for growth relative to its price. Notably, the stock has underperformed against the Sensex over various time frames, with a year-to-date return of -16.18% compared to the Sensex's 3.39%, reinforcing the view that it is fairly valued in the current market context.

Is Sanofi India technically bullish or bearish?

As of August 12, 2025, Sanofi India has shifted to a bearish technical trend, supported by negative indicators like MACD, Bollinger Bands, and KST, alongside a significant -24.37% return over the past year compared to the Sensex.

As of 12 August 2025, the technical trend for Sanofi India has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also reflect a bearish outlook in the same periods. Daily moving averages confirm a bearish trend. The KST is bearish on both weekly and monthly charts, while Dow Theory and OBV indicate a mildly bearish stance on the weekly and monthly time frames. Overall, the strength of the bearish trend is reinforced by the significant negative returns compared to the Sensex across various periods, particularly a -24.37% return over the past year.

Who are the top shareholders of the Sanofi India?

The top shareholders of Sanofi India include Hoechst Gmbh with 60.37%, Life Insurance Corporation of India - P & Gs Fund with 5.95%, mutual funds with 11.26%, foreign institutional investors at 5.57%, and individual investors holding 8.38%.

The top shareholders of Sanofi India include Hoechst Gmbh, which holds a significant 60.37% of the shares, making it the largest promoter. Other notable shareholders include the Life Insurance Corporation of India - P & Gs Fund, with a holding of 5.95%. Additionally, mutual funds collectively hold 11.26% through 18 schemes, while foreign institutional investors (FIIs) account for 5.57% through 134 entities. Individual investors also have a stake, holding 8.38% of the shares.